CJC-1295 vs sermorelin: comparing two GHRH analogs
Two peptides that ask the pituitary the same question — but on very different schedules.
TL;DR
- Sermorelin is short-acting and clears within minutes. CJC-1295 with DAC is long-acting, with a half-life of about a week in a study of healthy adults.
- Both work upstream — they ask the pituitary to release growth hormone. They do not contain growth hormone.
- The difference is duration, not one being "better." The human research on CJC-1295 is small and measured hormone levels, not health outcomes.
What it is
Both are GHRH analogs (in plain English: lab-made copies of growth-hormone-releasing hormone, the natural signal the brain sends to the pituitary to release growth hormone). Sermorelin came first — it is a 29-amino-acid fragment of natural GHRH. CJC-1295 is a modified version designed to last much longer in the bloodstream. Think of sermorelin as a phone call that gets answered and ends. Think of CJC-1295 as a phone call that stays on the line for days.
How it works
A GHRH analog binds the GHRH receptor on the pituitary gland — the small pea-sized gland tucked under the brain. The pituitary then releases a pulse of growth hormone (GH). GH travels to the liver, which produces IGF-1, the molecule that actually drives most of the downstream tissue effects. Sermorelin produces one pulse and clears quickly. CJC-1295 with DAC (in plain English: a chemical add-on called Drug Affinity Complex that binds the peptide to albumin and extends its half-life from minutes to days) produced sustained signaling in healthy adults, per Teichman et al. 2006.
Who asks about it
People come to this question when they have read about growth-hormone-releasing peptides and want to know how the two differ. The most-asked difference is how long each one lasts in the body.
What the research says
Sermorelin has a long clinical history and a peer-reviewed safety record. CJC-1295 with DAC has a shorter and smaller literature, including Ionescu and Frohman, 2006, a small study in healthy adults that found sustained IGF-1 elevation after a single dose. These studies measured hormone levels, not health outcomes.
What to know
The sustained CJC-1295 signal raises questions about long-term receptor desensitization that the literature has not fully resolved.
The Halftime POV
CJC-1295 and sermorelin ask the pituitary the same question on very different schedules. The human research on CJC-1295 is small, and it measured hormone levels, not health outcomes. That is the honest place to leave the comparison.
Related reading:
- Why CJC-1295 and ipamorelin are often discussed together
- Sermorelin: the GHRH analog primer
- IGF-1: what the lab actually measures
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- Ionescu M, Frohman LA, J Clin Endocrinol Metab, 2006 — Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
- Teichman SL et al., J Clin Endocrinol Metab, 2006 — Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is the main difference between CJC-1295 and sermorelin?
Half-life. Sermorelin is short-acting — quick pulse, quick gone. CJC-1295 (with the DAC modification) had a half-life of about a week in a study of healthy adults.
Is CJC-1295 stronger than sermorelin?
Not exactly stronger — longer-acting. In studies of healthy adults, a single CJC-1295 injection kept growth hormone levels raised for days. Sermorelin produces a short pulse. The difference is duration, not potency.
Which one is more researched in humans?
Sermorelin has decades of human use — the branded version (Geref) was FDA-approved in 1997 for pediatric growth hormone deficiency before being discontinued for commercial reasons. Compounded sermorelin is not FDA-approved. CJC-1295 has a smaller but more recent human research base in healthy adults.
